Cartesian Therapeutics, Inc.
Research Cartesian Therapeutics, Inc. (1S70) on Bullrun: market cap EUR 216.33M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1S70
- ExchangeF
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 216.33M
- Financial periodQ2 2026
- RevenueUSD 0
- Net incomeUSD 15.77M
- Free cash flow-USD 21.35M
Valuation Snapshot
latest market cap is EUR 216.33M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.80M | -USD 130.30M | -USD 79.40M | n/a | n/a | USD 125.14M | USD 12.68M | -USD 126.24M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 216.33M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cartesian Therapeutics, Inc.'s market cap?
Cartesian Therapeutics, Inc.'s market capitalization is EUR 216.33M.
What does Cartesian Therapeutics, Inc. do?
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.